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Candidate TB Drugs in Pipeline
Number of drugs in clinical stage of 
development
Number of pharmaceutical and biotech 
companies involved in drugs development 
projects
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Mycobacterium tuberculosis SysBorg : A systems Biology platform for 
infectious diseases using Systems Biology of whole organism
How does 
Latency arise
How is the 
pathogen cleared
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( CSIR Task force Network for in silico drug target discovery )
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W P­4 Identification of Chem ical library
W P­5 Microarray gene expression









 The sequencing of the Hum an G enom e created stir in the 
scientific 
   com m unity w ith the prom ise to m ake a rem arkable difference 
to   
   healthcare





The Prom ise of The Hum an G enom  
Sequence
16 FEBRUARY 2001 VO L 291 SCIENCE
11 JUNE 1998 VO L 393 NATURE
Provide the m olecular rationale for safe usage of low cost 
drugs in Public Healthcare system  To decipher the genom ic 
basis of variability in drug response.
 (eg: Epilepsy, M ental disorders etc)
To keep low­cost drugs/orphan drugs in the m arket by 
prom oting safe and effective usage. 
To provide “right dosage of right drug to the right patient”.
Avoiding adverse events to com m only used therapeutics 
using pharm acogenom ics.
Ref: Brahm achari SK. Annual Personalised M edicine 
Report 2007.
Pharm acogenom ics and 
Predictive Therapy for Com plex 
Diseases 
O SDD Phase­II
SysBorg
(G enom ic Data on 
Tuberculosis)
Virtual screening
(high pow er com putation)
O ther w eb based 
resources
Target Identification
Chem ical synthesisVirtual chem ical 
library
Protein Expression 
(data available on 
w eb)
Target isolation & 
structural determ ination
HITS
High Throughput Screening
Contributors
Students and Scientists
Univ’s & Acedem ia
Leads
Docking and Scoring 
by contributors
In vitro & in vivo validation
In silico Toxicity evaluation of Lead 
Lead O ptim ization
In silico anim al m odel for clinical trial
Clinical Trial
Pre­clinical
M anufacturing & M arketing by an organization
Bioinform atics tools
O utsourcing for 
Form ulation developm ent
Published on w eb
For open review
Contributors & 
Collaborators
O pen call for 
CRO ’s to Conduct 
further 
developm ent
Contributors  
subm issions
Target Validation
Tuberculosis Facts and 
Figures
Som eone in the world is newly infected with TB 
bacilli every  three second. 
Overall, one­third of the world's population is 
currently infected with the TB bacillus. 
5­10%  of people who are infected with TB becom e 
sick or infectious at som e tim e during 
their life. 
Left untreated, each person with active TB disease 
will infect on average between 10 and 
15 people every year 
450 000 new MDR­TB cases are estim ated to occur 
every year
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